Project Grant R21HD116010
Award Date
9/11/24
Completion Date
8/31/26
Dollars Obligated
$429K
Federal Agency
National Institute of Child Health and Human Development
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This federal Project Grant award, with an ID of R01NS137222, was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The total funding amount is $458,523.00, with a period of performance from July 1, 2024 to May 31, 2029. The objective of this grant is to identify molecular regulators of GABAergic systems that underlie the comorbidities of cognitive deficits and epilepsy in Down syndrome (DS). The research aims to determine how the...
This Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the cellular and synaptic mechanisms underlying cognitive disabilities in Down syndrome. The award to the University of Colorado-Denver will utilize a novel combination of two-photon microscopy, electrophysiology, chemogenetics, and pharmacological...
This $2,010,230 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under CFDA Program 93.865 (Child Health and Human Development Extramural Research) will support a multifaceted research study at the University of California, San Diego (UCSD) to investigate the relationship between cellular metabolism and neurodevelopmental deficits observed in Down syndrome. The research aims to comprehensively characterize the "nuclear-metabolic interplay"...
This Project Grant award of $2,357,335.00 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will enable a research team at Trustees of Boston University to study neuronal dysfunction in Down syndrome using cortical organoids and xenotransplantation models. The key products and services delivered through this funding include: Examining the impact of trisomy on neuronal activity, connectivity, and cellular composition in induced pluripotent stem...
This $3.44 million project grant from the Department of Health and Human Services National Institutes of Health Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), will fund research at the University of Massachusetts Medical School to suppress aneuploidy-associated phenotypes in Down syndrome. Specifically, the researchers will identify the mechanisms by which an extra copy of chromosome 21 affects nuclear structure and function in cells, investigate how...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $727,160.00 to Colorado State University to conduct research on severe/profound intellectual disability in individuals with Down syndrome. The project will recruit 90 children with Down syndrome to undergo comprehensive cognitive and developmental assessments over three data collection waves....
This $3.386 million project grant from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will fund research at Beth Israel Deaconess Medical Center to develop a potential treatment for Down syndrome. The grantee will assess the efficiency of using a modified CRISPR approach and single nucleotide polymorphism-based guide RNA targeting to silence one of three copies of human chromosome 21 in the Tc1 mouse model of Down syndrome. If successful, this research could...
The National Institutes of Health Trans-NIH Research Support program awarded a $4,010,262 Project Grant to the University of Illinois to study the role of amyloid precursor protein in neurogenesis and Alzheimer's disease pathology in Down syndrome. The three-year grant will support research examining how overexpression of amyloid precursor protein, which is located on chromosome 21 and thus triplicated in Down syndrome, impacts neural stem cell proliferation, neuronal differentiation, and...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,896,457.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on brain development in Down syndrome during fetal and early postnatal stages. The award will fund a retrospective study using routine clinical MRI data to identify early brain abnormalities in Down syndrome, with a...
This Project Grant award of $152,816 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports research to investigate the link between Down's syndrome (trisomy 21) and placentation defects. The key objectives are to: 1) Identify transcriptional differences between trisomy 21 and euploid (normal) induced pluripotent stem cell-derived syncytiotrophoblasts, 2) Assess the role of the...